2-5-dimethylcelecoxib and Asthma

2-5-dimethylcelecoxib has been researched along with Asthma* in 1 studies

Other Studies

1 other study(ies) available for 2-5-dimethylcelecoxib and Asthma

ArticleYear
KCNQ (Kv7) potassium channel activators as bronchodilators: combination with a β2-adrenergic agonist enhances relaxation of rat airways.
    American journal of physiology. Lung cellular and molecular physiology, 2014, Mar-15, Volume: 306, Issue:6

    KCNQ (Kv7 family) potassium (K(+)) channels were recently found in airway smooth muscle cells (ASMCs) from rodent and human bronchioles. In the present study, we evaluated expression of KCNQ channels and their role in constriction/relaxation of rat airways. Real-time RT-PCR analysis revealed expression of KCNQ4 > KCNQ5 > KCNQ1 > KCNQ2 > KCNQ3, and patch-clamp electrophysiology detected KCNQ currents in rat ASMCs. In precision-cut lung slices, the KCNQ channel activator retigabine induced a concentration-dependent relaxation of small bronchioles preconstricted with methacholine (MeCh; EC50 = 3.6 ± 0.3 μM). Bronchoconstriction was also attenuated in the presence of two other structurally unrelated KCNQ channel activators: zinc pyrithione (ZnPyr; 1 μM; 22 ± 7%) and 2,5-dimethylcelecoxib (10 μM; 24 ± 8%). The same three KCNQ channel activators increased KCNQ currents in ASMCs by two- to threefold. The bronchorelaxant effects of retigabine and ZnPyr were prevented by inclusion of the KCNQ channel blocker XE991. A long-acting β2-adrenergic receptor agonist, formoterol (10 nM), did not increase KCNQ current amplitude in ASMCs, but formoterol (1-1,000 nM) did induce a time- and concentration-dependent relaxation of rat airways, with a notable desensitization during a 30-min treatment or with repetitive treatments. Coadministration of retigabine (10 μM) with formoterol produced a greater peak and sustained reduction of MeCh-induced bronchoconstriction and reduced the apparent desensitization observed with formoterol alone. Our findings support a role for KCNQ K(+) channels in the regulation of airway diameter. A combination of a β2-adrenergic receptor agonist with a KCNQ channel activator may improve bronchodilator therapy.

    Topics: Acetylcholine; Adrenergic beta-2 Receptor Agonists; Animals; Anthracenes; Asthma; Bronchi; Bronchoconstriction; Bronchoconstrictor Agents; Bronchodilator Agents; Carbamates; Ethanolamines; Formoterol Fumarate; KCNQ Potassium Channels; Keratolytic Agents; Male; Membrane Transport Modulators; Methacholine Chloride; Myocytes, Smooth Muscle; Organometallic Compounds; Patch-Clamp Techniques; Phenylenediamines; Potassium Channel Blockers; Pyrazoles; Pyridines; Rats; Rats, Sprague-Dawley; Sulfonamides

2014